User login
Key clinical point: Patritumab deruxtecan (HER3-DXd) showed meaningful clinical efficacy and a manageable safety profile across breast cancer (BC) subtypes in heavily pretreated patients with human epidermal growth factor receptor 3 (HER3)-expressing metastatic BC.
Major finding: The objective response rate was 30.1% (95% CI 21.8%-39.4%) in hormone receptor-positive/HER2-negative BC, 22.6% (95% CI 12.3%-36.2%) in triple-negative BC, and 42.9% (95% CI 17.1%-71.1%) in HER2-positive BC. Although 71.4% of patients reported grade ≥3 treatment-emergent adverse events (TEAE), the overall rate of treatment discontinuation due to TEAE was low (9.9%).
Study details: Findings are from a phase I/II trial including 182 heavily pretreated patients with HER3-expressing advanced BC who received HER3-DXd.
Disclosures: This trial was sponsored by Daiichi Sankyo Co., Ltd. Nine authors declared being employees of or holding stocks and other ownership interests in Daiichi Sankyo. The other authors declared ties with various sources, including Daiichi Sankyo.
Source: Krop IE et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I/II trial. J Clin Oncol. 2023 (Oct 6). doi: 10.1200/JCO.23.00882
Key clinical point: Patritumab deruxtecan (HER3-DXd) showed meaningful clinical efficacy and a manageable safety profile across breast cancer (BC) subtypes in heavily pretreated patients with human epidermal growth factor receptor 3 (HER3)-expressing metastatic BC.
Major finding: The objective response rate was 30.1% (95% CI 21.8%-39.4%) in hormone receptor-positive/HER2-negative BC, 22.6% (95% CI 12.3%-36.2%) in triple-negative BC, and 42.9% (95% CI 17.1%-71.1%) in HER2-positive BC. Although 71.4% of patients reported grade ≥3 treatment-emergent adverse events (TEAE), the overall rate of treatment discontinuation due to TEAE was low (9.9%).
Study details: Findings are from a phase I/II trial including 182 heavily pretreated patients with HER3-expressing advanced BC who received HER3-DXd.
Disclosures: This trial was sponsored by Daiichi Sankyo Co., Ltd. Nine authors declared being employees of or holding stocks and other ownership interests in Daiichi Sankyo. The other authors declared ties with various sources, including Daiichi Sankyo.
Source: Krop IE et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I/II trial. J Clin Oncol. 2023 (Oct 6). doi: 10.1200/JCO.23.00882
Key clinical point: Patritumab deruxtecan (HER3-DXd) showed meaningful clinical efficacy and a manageable safety profile across breast cancer (BC) subtypes in heavily pretreated patients with human epidermal growth factor receptor 3 (HER3)-expressing metastatic BC.
Major finding: The objective response rate was 30.1% (95% CI 21.8%-39.4%) in hormone receptor-positive/HER2-negative BC, 22.6% (95% CI 12.3%-36.2%) in triple-negative BC, and 42.9% (95% CI 17.1%-71.1%) in HER2-positive BC. Although 71.4% of patients reported grade ≥3 treatment-emergent adverse events (TEAE), the overall rate of treatment discontinuation due to TEAE was low (9.9%).
Study details: Findings are from a phase I/II trial including 182 heavily pretreated patients with HER3-expressing advanced BC who received HER3-DXd.
Disclosures: This trial was sponsored by Daiichi Sankyo Co., Ltd. Nine authors declared being employees of or holding stocks and other ownership interests in Daiichi Sankyo. The other authors declared ties with various sources, including Daiichi Sankyo.
Source: Krop IE et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I/II trial. J Clin Oncol. 2023 (Oct 6). doi: 10.1200/JCO.23.00882